7/17/09 update
With Goldman Sachs bringing home the gold, it was party time on Wall Street. And when the trading week ended, the Nasdaq Composite Index was up 20.04% CYTD, or Contest Year To Date, (vs. up 11.74% CYTD a week ago). Biotechs also joined in the merriment, with the Nasdaq Biotech Index closing Friday up 3.72% CYTD (vs. up .44% CYTD a week ago) and the Contest median closing up 13.08% CYTD (vs. up 6.93% CYTD a week ago).
RKRW's portfolio held on to first place, but No. 2 GENE's portfolio is now nipping at RKRW's heels and MIKE's portfolio has taken third place from GEORGIA's portfolio (which was creamed by OSCI). (Guess which portfolio has galloped into the No. 4 slot.)
The week's closing CYTD percentages are: RKRW up 71.85%, GENE up 68.99%, MIKE up 60.92%.
At Friday's close, 22 of the 32 Contest portfolios were in the black and 19 of the 32 were beating the NBI.
Have a fun weekend biotechies!
Below is the Top Ten list on 7/17/09:
7/17/09
Rank Name Profit/Loss
1 RKRW 71,854
2 GENE 68,985
3 MIKE 60,924
4 BULBA 50,535
5 GEORGIA 44,335
6 ROBERT 41,076
7 SCARAM 35,537
8 ENZYME 29,375
9 MOPGCW 28,090
10 NIGEL 26,429
(All corrections, especially adjustments for splits, greatly appreciated.) |
